<DOC>
	<DOC>NCT01748539</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. Pharmacokinetics of KHK4827 will also be assessed.</brief_summary>
	<brief_title>A Phase 2 Clinical Study of KHK4827</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject has had stable moderate to severe plaque psoriasis for at least 6 months. Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator. Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline. Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medicationinduced, or medicationexacerbated psoriasis. Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis. Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol. Subject has used the following therapies within 14 days of the first dose: topical calcineurin inhibitors including tacrolimus , topical vitamin A, activated form D3 or activated form D3 analogue preparations, weak through strong topical steroids (excluding application on the scalp, axillae, and groin) Subject has used the following therapies within 28 days of the first dose: any other systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates, steroids), UVA therapy (with or without psoralen), very strong or strongest topical steroid, tar therapy Subject has used the following therapies within 3 months of the first dose: adalimumab, etanercept, infliximab, or live vaccines Subject has used ustekinumab within 6 months of the first dose Subject has previously used an antiinterleukin17 biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>